(3.236.117.38)
Users online: 3141    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 3
First page : ( 1467) Last page : ( 1473)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00268.1

Assessment of amikacin Induced Ototoxicity in a Neonatal ICU Setup-An experience from tertiary care Teaching Hospital in South India

Dilip Silpa1, Dr. Bendapudi Perraju2, Bhaskaran Renjitha3, Roshni P R4,*

14th Semester M. Pharm, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Viswa Vidhyapeetham, Kochi

2Consultant, Department of Neonatology, Amrita Institute of Medical Sciences and Research Centre, Kochi

3Lecturer, Department of Biostatistics, Amrita Institute of Medical Sciences and Research Centre, Kochi

4Assistant Professor, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi

*Corresponding Author E-mail: roshnipr@aims.amrita.edu

Online published on 22 April, 2020.

Abstract

Objectives

This study aimed to assess the prevalence of Amikacin induced ototoxicity in neonates in a tertiary care hospital and to elucidate the possible risk factors. Design: A retroprospective study on two hundred and sixty neonates admitted to the neonatal intensive care unit (NICU), who were treated with Amikacin. Ototoxicity was assessed by measuring the hearing impairment in neonates using Brainstem Evoked Response Audiometry (BERA) at the time of discharge. A repeat BERA was done for those who failed during the initial BERA.

Results

The prevalence of Amikacin induced ototoxicity in neonates was found to be 11.2% (29 out of 260). Among these 29, only 16 had a follow up BERA and 8 of them showed persistent hearing impairment at the 3 months BERA. Genetic anomalies had showed a significant association with hearing impairment (P value = 0.001). Among the 16 who were diagnosed with a genetic condition 43.8% of them had hearing impairment.. The value of CRP (mg/dl) during the 1st course of Amikacin therapy had shown a border line significance (P value =0.067) with hearing impairment. Conclusion: Genetic abnormalities have shown a significant relationship with hearing impairment, hence the use of Amikacin in such neonates should be monitored. We attribute the low prevalence rate of ototoxicity in the NICU population, even in the absence of a therapeutic drug monitoring system for Amikacin to the dosage regimen being used and to the good clinical practices being followed in the NICU.

Top

Keywords

Amikacin, Neonates, Ototoxicity.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
498,136,205 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.